Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Get Alerts CATB Hot Sheet
Join SI Premium – FREE
BOSTON--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:
- H.C. Wainwright Global Life Sciences Conference. Presentations will be available on-demand from March 9-10, 2021.
- Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:00am ET.
Webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will be available for 30 days following the event.
Catabasis is also participating in Guggenheim Healthcare Talks, 2021 Genomic Medicines & Rare Disease, on April 1, 2021.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005131/en/
Investor relations:
Andrea Matthews
[email protected]
Media:
Elizabeth Higgins
[email protected]
Source: Catabasis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Four ONDA Partners Earn Placement on D Magazine’s Best Lawyers List
- Faraday Future Receives Letter from Nasdaq Regarding Form 10-K Filing
- Riding the Trend: Baros Maldives' Immersive Water Therapy
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
H.C. Wainwright, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!